<!DOCTYPE html>
<html>
<head>
    <title>BREAKING: Federal Register: Epidermolysis Bullosa: Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry; Availability</title>
    <meta charset="UTF-8">
    <style>
        body { font-family: Georgia, serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { border-bottom: 2px solid #333; }
        .breaking { background: #fff3cd; border-left: 4px solid #dc3545; padding: 15px; }
        .source { background: #f8f9fa; padding: 10px; margin-top: 20px; font-size: 0.9em; }
        .timestamp { color: #666; }
    </style>
</head>
<body>
    <h1>BREAKING: Federal Register: Epidermolysis Bullosa: Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry; Availability</h1>
    <p class="timestamp">Published: 2019-07-01 | Source: Federal Register</p>
    <div class="breaking">
        <p><strong>The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry entitled "Epidermolysis Bullosa: Developing Drugs for Treatment of Cutaneous Manifestations." The purpose of this guidance is to assist sponsors with the development of drugs for treatment or prevention of the serious cutaneous manifestations of the heterogeneous group of disorders collectively known as epidermolysis bullosa (EB). This guidance focuses on drug development and trial de...</strong></p>
    </div>
    <h2>Document Details</h2>
    <p><strong>Document Type:</strong> Notice</p>
    <p><strong>Agency:</strong> Health and Human Services Department, Food and Drug Administration</p>
    <p><strong>Document Number:</strong> 2019-13969</p>
    <p><strong>Publication Date:</strong> 2019-07-01</p>
    <h2>Official Source</h2>
    <p>Read the full document at: <a href="https://www.federalregister.gov/documents/2019/07/01/2019-13969/epidermolysis-bullosa-developing-drugs-for-treatment-of-cutaneous-manifestations-guidance-for">https://www.federalregister.gov/documents/2019/07/01/2019-13969/epidermolysis-bullosa-developing-drugs-for-treatment-of-cutaneous-manifestations-guidance-for</a></p>
    <div class="source"><strong>Source:</strong> Federal Register - 2019-13969</div>
    <p><a href="index.html">Back to Breaking News Wire</a></p>
</body>
</html>
